Application of Kenpaullone in preparation of medicine capable of preventing or treating cerebral amyloid angiopathy

Abstract

The invention provides application of Kenpaullone in preparation of a medicine capable of preventing or treating cerebral amyloid angiopathy. An experiment discovers that the Kenpaullone can increaseexpression of ADAM10 on a cell level but does not accelerate the expression of mRNA. In a further animal experiment APP / PS1 mouse model, a result discovers that the Kenpaullone obviously lightens cerebral vessel amyloid precipitation. An experiment proves for the first time that the Kenpaullone can increase the expression of the ADAM10, the amyloid metabolic pathway of APP can be converted into anon-amyloid metabolic pathway, and the generation of A[beta] which can be gathered and can precipitate is reduced. Research discovers that a Kenpaullone derivative Alsterpaullone(ALS) accelerates theprotein expression of the ADAM10 in SH-SY5Y cells; and AT7519 which is also CDK inhibitor does not affect the expression of the ADAM10 in SYSY5Y cells. All above research provides a clinical experiment guidance meaning for treatment of cerebral vessel amyloid degeneration and further medicine research and development.

Description

[0001] Cross References to Related Applications [0002] This application claims the priority of Chinese patent application 2020110442206 filed on September 28, 2020, the disclosure content of which is incorporated herein by reference. technical field [0003] The invention relates to the medical use of camparone, in particular to the application of camparone in the preparation of medicines for preventing or treating amyloid cerebrovascular disease. Background technique [0004] Cerebral amyloid angiopathy (CAA), also known as cerebral congophilic angiopathy (cerebrovascular; troyiofdosiS), is a common vascular disease in the elderly. Mainly involves cerebral cortical arterioles, medium arteries, arterioles and capillaries, manifested as progressive deposition of Aβ on the vessel wall (Biffi A, Greenberg SM (2011) Cerebralamyloid angiopathy: a systematic review. J Clin Neurol 7:1-9) . Cerebrovascular amyloidosis is considered to be an important cause of spontaneous intracr...

AI Technical Summary

Problems solved by technology

Although in the past 20 years, major pharmaceutical companies and scientific research institutions around the world have successively invested a lot of money in the research and development of drugs for the treatment of cerebrovascular amyloidosis, but so far have not successfully developed drugs for the etiological treatment of Aβ deposition.

Images